Brain Outcomes With Lifestyle Change in Down Syndrome
BOLD
The Impact of Weight Loss on Alzheimer's Disease Risk in Adults With Down Syndrome
1 other identifier
interventional
81
1 country
1
Brief Summary
The goal of this study is to determine if weight loss or changes in dietary intake can help prevent of delay adults with Down syndrome from developing Alzheimer's Disease Adults with Down syndrome without dementia will be randomized to either a weight loss group or a general health education control group. The weight loss group will be asked to follow a reduced energy diet, attend monthly education sessions delivered remotely and self-monitor diet and body weight using commercially available web-based applications. The control group will be asked to attend remotely delivered monthly education sessions on general health education topics. All participants will come to the University of Kansas Medical Center, 3 times across 12 months for a blood draw, cognitive testing, a MRI, assessment of height and weight, and assessment of diet intake.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Oct 2024
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 2, 2023
CompletedFirst Posted
Study publicly available on registry
August 14, 2023
CompletedStudy Start
First participant enrolled
October 22, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 30, 2027
March 11, 2026
March 1, 2026
2.9 years
August 2, 2023
March 9, 2026
Conditions
Outcome Measures
Primary Outcomes (3)
Plasma Amyloid beta 42:40 ratio
Examines the amount of amyloid beta in a person's brain, measured by a blood draw.
Baseline, 6, 12 months
Neurofilament light
Examines the amount of Neurofilament light in a person's brain, measured by a blood draw.
Baseline, 6, 12 months
Weight
Examines how much a person weights, measured by standing on a scale.
Baseline, 6, 12 months
Secondary Outcomes (9)
Dietary Intake
Baseline, 6, 12 months
Skin carotenoid content
Baseline, 6, 12 months
Plasma Phosphorylated Tau
Baseline, 6, 12 months
Glial Fibrillary Acidic Protein
Baseline, 6, 12 months
Brian Volume
Baseline, 12 months
- +4 more secondary outcomes
Other Outcomes (6)
Height
Baseline, 6, 12 months
Waist circumference
Baseline, 6, 12 months
Attendance at education sessions
Across 12 months
- +3 more other outcomes
Study Arms (2)
Weight Loss
EXPERIMENTAL* Follow a reduced calorie diet daily for 12 months. * Attend monthly behavioral counseling/education
General Health Education Control
ACTIVE COMPARATOR\- Attend monthly health education sessions about general health.
Interventions
A reduced calorie diet which uses frozen meals purchased at the store and focuses on increasing fruits and vegetables associated with brain health.
Monthly health education sessions delivered remotely.
Eligibility Criteria
You may qualify if:
- Diagnosis of Down syndrome
- BMI of 25 to 50 kg/m2
- Ability to communicate through spoken language.
- Ability to come to the University of Kansas Medical Center 3 times across 1 year for outcomes testing
- Living at home with a parent/guardian, or in a supported living environment with a caregiver who assists with food shopping, meal planning, and meal preparation and agrees to serve as a study partner including providing transportation to our facilities for study assessments.
You may not qualify if:
- Diagnosis of dementia
- Insulin dependent diabetes
- Participation in a weight management program involving diet or physical activity in the past 6 mos.
- Dairy allergy
- Serious medical risk (e.g., cancer, recent heart attack, stroke, pregnancy, angioplasty)
- Unwilling to be randomized
- Contraindications for MRI, including metal implants or devices incompatible with MRI such as pacemakers, claustrophobia, and inability to lay in a supine position
- Use of GLP-1 medications
- Use of anti-amyloid medications
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 2, 2023
First Posted
August 14, 2023
Study Start
October 22, 2024
Primary Completion (Estimated)
September 30, 2027
Study Completion (Estimated)
September 30, 2027
Last Updated
March 11, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share